Specialized, state-of-the-art clinical research unit established in 2003 in Southern California and globally recognized for metabolic drug and device clinical trials.

  • First-in-Human, First-in-Patient studies
  • Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) studies
  • Proof of Concept (PoC), Proof of Mechanism (PoM), Mechanism of Action (MoA) studies
  • Bioequivalence and drug/drug interaction studies
  • Full spectrum of automated glucose clamp studies
  • 21,000 sq ft and 30+ treatment beds
  • Eight-week in-patient extended stay capabilities
  • CLIA-certified laboratory
  • USP 797/800 standard clean room
  • 24/7 on-site medical and clinical teams
Read More